🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Oligoprogression

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP) NCT06367972Phase 2, Phase 31 site📍 Houston M.D. Anderson Cancer Center · Tests: Local Consolidation Therapy, Next-line Systemic Therapy A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC NCT07193641Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Spatially Fractionated Radiotherapy (SFRT)+Stereotactic Body Radiation Therapy (SBRT), The systemic therapy Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression NCT05784428NA14 sites📍 Kelowna📍 Prince George📍 Surrey Robert Olson · Tests: Single fraction SABR, Multiple fraction SABR, QoL reporting alone, QoL reporting, symptom screen and healthcare provide… A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases NCT04299646Phase 230 sites📍 Albi📍 Angers📍 Bordeaux Centre Francois Baclesse · Tests: Steretactic radiotherapy COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study NCT05301881Phase 27 sites📍 Alkmaar📍 Amsterdam📍 Arnhem The Netherlands Cancer Institute · Tests: Surgery, Radiotherapy, Radiofrequent ablation Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma NCT07112170NA1 site📍 Toronto University Health Network, Toronto · Tests: Stereotactic Body Radiation Therapy (SBRT) Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) NCT06925984NA5 sites📍 Brussels📍 Ghent📍 Kortrijk Jules Bordet Institute · Tests: SBRT Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation. NCT05102747NA15 sites📍 Bordeaux📍 Bordeaux📍 Brest Centre Francois Baclesse · Tests: Hypofractionated SRT (stereotactic radiotherapy), Historical single-dose SRS (stereotactic radiosurgery) Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy NCT04892953Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Carboplatin, Durvalumab, Gemcitabine, Local Consolidation Therapy, Nab-paclitaxel Stereotactic Magnetic Resonance Guided Radiation Therapy NCT04115254NA2 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: MR-guided Linac Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy NCT06870942Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Maintenance first-line treatment plus radiation therapy A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab NCT07619599Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomo… Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma NCT04974671Phase 21 site📍 New Haven Yale University · Tests: Stereotactic Body Radiation Therapy SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722Phase 22 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: SBRT combined with Nimotuzumab followed by Tislelizumab Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer NCT06260033Phase 22 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC) NCT07038304Phase 22 sites📍 Groningen📍 Nijmegen University Medical Center Groningen · Tests: Metastasis directed radiotherapy Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) NCT06103669NA1 site📍 Sacramento University of California, Davis · Tests: Ablative local therapy Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers NCT06918951NA1 site📍 Surrey British Columbia Cancer Agency · Tests: Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer NCT04989725Phase 21 site📍 Montreal Centre hospitalier de l'Université de Montréal (CHUM) · Tests: Standard arm, Experimental arm SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy NCT05990192Phase 27 sites📍 Leeds📍 Leicester📍 Manchester Institute of Cancer Research, United Kingdom · Tests: Niraparib oral capsule, SBRT Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer NCT04838899NA1 site📍 Toronto Sunnybrook Health Sciences Centre · Tests: Stereotactic Body Radiation Therapy (SABR) Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) NCT06101290NA1 site📍 Sacramento University of California, Davis · Tests: Ablative local therapy SBRT in HCC With Oligoprogression on First-line Immunotherapy NCT06434480NA1 site📍 Hong Kong Chinese University of Hong Kong · Tests: Stereotactic Body Radiation Therapy (SBRT) Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer NCT03546829Phase 11 site📍 Philadelphia Abramson Cancer Center at Penn Medicine · Tests: Vancomycin, Precision hypofractionated radiation LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE) NCT06103682NA1 site📍 Sacramento University of California, Davis · Tests: Ablative local therapy Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer NCT06523673Phase 31 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Stereotactic Body Radiotherapy, second-line systemic therapy Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer NCT06927635Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Stereotactic Body Radiation Therapy (SBRT), Systemic therapy SMC Radiation Oncology SABR Cohort for Oligometastasis NCT07121335n/a1 site📍 Seoul Samsung Medical Center · Tests: Stereotactic body radiotherapy (SBRT) Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma NCT06014827Phase 22 sites📍 Duarte📍 New Haven City of Hope Medical Center · Tests: Biospecimen Collection, Computed Tomography, Osimertinib, Positron Emission Tomography, Stereotactic Body Radiation The… Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer NCT06686771Phase 375 sites📍 Phoenix📍 Duarte📍 Irvine Canadian Cancer Trials Group · Tests: SBRT, First or second-line standard of care therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy